The global cancer immunotherapy market was valued at more than US$ 92.11 billion in 2024. It is anticipated to increase at a CAGR of 12.84% between 2024 and 2031. The worldwide cancer immunotherapy ...

Find out more about the emerging field of glycobiology, which could potentially lead to a new type of cancer immunotherapy.

TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies ...

Opioids are often first-line treatments for cancer-related pain, but they can suppress the immune system and reduce the ...

A deep learning radiomic biomarker has been developed and validated to predict responses to immune checkpoint inhibitors in ...

New treatments and adverse events impacting patient quality of life were among the topics of interest in 2024.

New data suggests researchers may have found one of their most promising candidates yet for the next generation in ...

CTLA-4 is an immune checkpoint receptor that suppresses T cell ... This mechanism has made CTLA-4 inhibitors an essential part of cancer immunotherapy, particularly in treating advanced-stage ...

New insights into the impact of checkpoint inhibitors on the immune system may enhance cancer treatment strategies. A ...